Screening and clinical significance of lymph node metastasis-related genes within esophagogastric junction adenocarcinoma

Cancer Med. 2021 Aug;10(15):5088-5100. doi: 10.1002/cam4.4065. Epub 2021 Jun 21.

Abstract

Background: Despite recent improvements in treatment technologies, such as surgical resection and chemoradiotherapy, the prognosis of patients with esophagogastric junction adenocarcinoma (EJA) remains poor due to early lymph node metastasis. Since few studies have investigated genes associated with lymph node metastasis in EJA, we aimed to screen lymph node metastasis-associated genes and clarify their expression status and prognostic significance in EJA.

Methods: The differential frequency of mutations between carcinoma and para-carcinoma tissues from 199 cases with EJA was detected using targeted next-generation sequencing (tNGS). Following a stratified analysis to determine that gender has no effect on the frequency of gene mutations, lymph node metastasis-related genes, including CDK6, MET, NOTCH1, and LRP1B, were screened, and CDK6 and LRP1B were selected for further study as they displayed significant differences in mutation rates. Differences in their expression status were verified using immunohistochemical (IHC) staining in 18 CDK6- and 17 LRP1B-mutated samples and a randomly matched control group.

Results: tNGS revealed that CDK6 and LRP1B mutation frequencies were significantly different between EJA cases with (N ≥ 1) or without (N = 0) lymph node metastasis. In particular, CDK6 mutation frequency was expected less, whereas that of LRP1B was remarkably higher in cases with stage N0 than in those with stage N ≥ 1. IHC staining confirmed significant differences in CDK6 and LRP1B expression status between the study and control cohorts. Chi-square tests revealed that a high CDK6 expression status correlated significantly with smoking history (p = 0.044), T stage (p = 0.035), N stage (p = 0.000), and advanced TNM stage (p = 0.001) in EJA, whereas a high LRP1B expression status only correlated with BMI (p = 0.013) and N stage (p = 0.000). Furthermore, as confirmed by survival status investigation, a high LRP1B expression status predicted good prognosis, and a high CDK6 expression status was an independent predictor of poor prognosis in patients with EJA.

Conclusions: Taken together, the findings of this study demonstrate that a high CDK6 and LRP1B expression status promotes and inhibits lymph node metastasis in patients with EJA, respectively, suggesting that both CDK6 and LRP1B are significantly potential predictors of lymph node metastasis and prognosis in EJA.

Keywords: CDK6; LRP1B; esophagogastric junction adenocarcinoma; lymph node metastasis; targeted next-generation sequencing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / genetics*
  • Adenocarcinoma / mortality
  • Adenocarcinoma / secondary
  • Body Mass Index
  • Chi-Square Distribution
  • Cyclin-Dependent Kinase 6 / genetics*
  • Esophagogastric Junction*
  • Female
  • Gene Expression
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Lymphatic Metastasis / genetics*
  • Male
  • Middle Aged
  • Mutation Rate
  • Neoplasm Staging
  • Proto-Oncogene Proteins c-met / genetics
  • Receptor, Notch1 / genetics
  • Receptors, LDL / genetics*
  • Smoking / genetics
  • Stomach Neoplasms / genetics*
  • Stomach Neoplasms / mortality
  • Stomach Neoplasms / pathology

Substances

  • LRP1B protein, human
  • NOTCH1 protein, human
  • Receptor, Notch1
  • Receptors, LDL
  • MET protein, human
  • Proto-Oncogene Proteins c-met
  • CDK6 protein, human
  • Cyclin-Dependent Kinase 6